Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications

Thorax

Volumn 68, Issue 1, 2013, Pages 114-116

  Singh, Sonal ^a   Loke, Yoon K ^b   Enright, Paul ^c   Furberg, Curt D ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c UNIVERSITY OF ARIZONA   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE; PLACEBO; TIOTROPIUM BROMIDE;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SUPRAVENTRICULAR TACHYCARDIA;

EID: 84871362143     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2011-201275     Document Type: Note

References (24)

1. Miniño AM, Xu JQ, Kochanek KD. Deaths: preliminary data for 2008. Natl Vital Stat Rep 2010;59. http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59-02. pdf (accessed 28 May 2012).
2. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan, Canada. Ann Epidemiol 2006;16:63-70. (Pubitemid 41783891)
3. Tashkin DP, Celli B, Senn S, et al; for the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
4. Kesten S, Jara M, Wentworth C, et al. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130:1695-703. (Pubitemid 46033421)
5. Nakamura T, Nakanishi T, Haruta T, et al. Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm 2010;7:187-95.
6. Simmons K, Khan J, Hussan A, et al. Characterising cardiovascular safety profile of muscarinic antagonist, ipratropium. British Society for Cardiovascular Research 2010 Autumn Meeting: abstracts: 02. Heart 2011;97:e1.
7. Simmons K, Hussain A, Maddock H. Further investigation into the cardiovascular safety profile of muscarinic antagonist, ipratropium. Proceedings of the British Pharmacological Society. http://www.pa2online.org/abstracts/ vol8issue1abst049p.pdf (accessed 24 Jun 2011).
8. van Vlymen JM, Parlow JL. The effects of reversal of neuromuscular blockade on autonomic control in the perioperative period. Anesth Analg 1997;84:148-54. (Pubitemid 27020975)
9. Mathew J, Hunsberger S, Fleg J, et al. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 2000;118:914-22.
10. Spiriva HandiHaler (Tiotropium Bromide) Inhalation Powder Company: Boehringer Ingelheim. 2004. Application No.: 021395. http://www.accessdata.fda. gov/drugsatfda-docs/nda/2004/21-395-Spiriva.cfm (accessed 7 Oct 2011).
11. Bigger JT, Fleiss JL, Rolnitzky LM, et al. The ability of several short-term measures of RR variability to predict mortality after myocardial infarction. Circulation 1993;88:927-34. (Pubitemid 23264007)
12. Anthonisen NR, Connett JE, Enright PL, et al; for the Lung Health Study Research Group. Hospitalizations and mortality in the lung health study. Am J Respir Crit Care Med 2002;166:333-9. (Pubitemid 34864422)
13. Covelli H, Bhattacharya S, Cassino C, et al. Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy 2005;25:1708-18. (Pubitemid 41790093)
14. Morganroth J, Golisch W, Kesten S. Eletrocardiographic monitoring in COPD patients receiving tiotropium. COPD 2004;1:181-90.
15. Electronic Medicines Compendium. Spiriva Respimat - Summary of Product Characteristics. 2011. http://www.medicines.org.uk/EMC/medicine/20547/PIL/ Spiriva%20Respimat%202.5%20micrograms%20solution%20for%20inhalation (accessed 28 May 2012).
16. Boehringer Ingelheim. Briefing Document, Tiotropium-Pulmonary Allergy Drug Advisory Committee, November 2009. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary- AllergyDrugsAdvisory Committee/UCM190466.pdf (accessed 12 Oct 2011).
17. Division of Pulmonary-Allergy Drugs Advisory Committee and Office of Surveillance and Epidemiology, US Food and Drug Administration. FDA Briefing Document. 2009. http://www.fda.gov/downloads/advisorycommittees/ committeesmeeting materials/drugs/pulmonary-allergydrugsadvisorycommittee/ ucm190463.pdf (accessed 28 May 2012).
18. Worth H, Chung KF, Felser JM, et al. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011;105:571-9.
19. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439-50.
20. Singh S, Loke YK, Enright PL, et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. Br Med J 2011;342:d3215.
21. Vogelmeier C, Hederer B, Glaab T, et al POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093-103.
22. Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients. http://clinicaltrials.gov/ct2/show/ NCT00563381? term=NCT00563381&rank=1 (accessed 28 May 2012).
23. Greenland S. Null misinterpretation in statistical testing and its impact on health risk assessment. Prev Med 2011;53:225-8.
24. MHRA. Drug Safety Update Nov 2011; Vol 4: Issue 4: H2. http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con099854.pdf (accessed 28 May 2012).